Ming-May Lai1, Cheng-Chieh Lin2, Che-Chen Lin3, Chiu-Shong Liu1, Tsai-Chung Li4, Chia-Hung Kao5. 1. Department of Family Medicine, China Medical University & Hospital, Taichung, Taiwan. 2. Department of Family Medicine, China Medical University & Hospital, Taichung, Taiwan; Institute of Health Care Administration, College of Public Health, China Medical University & Hospital, Taichung, Taiwan; Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan. 3. Management Office for Health Data, China Medical University & Hospital, Taichung, Taiwan. 4. Department of Healthcare Administration, College of Health Science, Asia University, Taichung, Taiwan; Graduate Institute of Biostatistics & Chinese Medicine Science and Biostatistics Center, China Medical University, Taichung, Taiwan. 5. Graduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan. Electronic address: d10040@mail.cmuh.org.tw.
Abstract
OBJECTIVE: To estimate the risk of head injury or fracture requiring hospitalization in patients treated with zolpidem. PATIENTS AND METHODS: We identified 8188 patients 18 years and older who had received a first prescription for zolpidem between January 1, 2000, and December 31, 2009, and compared them with 32,752 age- and sex-matched patients who had not used sedative-hypnotic agents. Both cohorts were followed up for at least 1 year or until hospitalization for head injury or fracture (major injury). Hazard ratios (HRs) and 95% CIs were calculated by comparing the incidence of major injury requiring hospitalization between the zolpidem user and comparison cohorts, including age groups 18 to 54 and 55 years or more, using a Cox proportional hazards regression analysis. RESULTS: The adjusted HR for major injury in zolpidem users was 1.67 (95% CI, 1.19-2.34). The adjusted HR for major injury in zolpidem users in the younger cohort (aged 18-54 years) was 1.70 (95% CI, 1.15-2.51) and in the older cohort (aged ≥55 years) was 1.57 (95% CI, 0.78-3.13). The adjusted HR for major injury in zolpidem users increased when the zolpidem dosage increased (HR, 2.04; 95% CI, 1.32-3.13 for 71-800 mg/y; HR, 4.37; 95% CI, 2.12-9.01 for 801-1600 mg/y; and HR, 4.74; 95% CI, 2.38-9.42 for >1600 mg/y). CONCLUSION: The long-term use of zolpidem is associated with a significantly greater risk of head injury or fracture requiring hospitalization than in patients who do not use sedative-hypnotic agents (P<.001), particularly in the younger (aged 18-54 years) patients.
OBJECTIVE: To estimate the risk of head injury or fracture requiring hospitalization in patients treated with zolpidem. PATIENTS AND METHODS: We identified 8188 patients 18 years and older who had received a first prescription for zolpidem between January 1, 2000, and December 31, 2009, and compared them with 32,752 age- and sex-matched patients who had not used sedative-hypnotic agents. Both cohorts were followed up for at least 1 year or until hospitalization for head injury or fracture (major injury). Hazard ratios (HRs) and 95% CIs were calculated by comparing the incidence of major injury requiring hospitalization between the zolpidem user and comparison cohorts, including age groups 18 to 54 and 55 years or more, using a Cox proportional hazards regression analysis. RESULTS: The adjusted HR for major injury in zolpidem users was 1.67 (95% CI, 1.19-2.34). The adjusted HR for major injury in zolpidem users in the younger cohort (aged 18-54 years) was 1.70 (95% CI, 1.15-2.51) and in the older cohort (aged ≥55 years) was 1.57 (95% CI, 0.78-3.13). The adjusted HR for major injury in zolpidem users increased when the zolpidem dosage increased (HR, 2.04; 95% CI, 1.32-3.13 for 71-800 mg/y; HR, 4.37; 95% CI, 2.12-9.01 for 801-1600 mg/y; and HR, 4.74; 95% CI, 2.38-9.42 for >1600 mg/y). CONCLUSION: The long-term use of zolpidem is associated with a significantly greater risk of head injury or fracture requiring hospitalization than in patients who do not use sedative-hypnotic agents (P<.001), particularly in the younger (aged 18-54 years) patients.
Authors: Christine M Swanson; Wendy M Kohrt; Orfeu M Buxton; Carol A Everson; Kenneth P Wright; Eric S Orwoll; Steven A Shea Journal: Metabolism Date: 2017-12-09 Impact factor: 8.694
Authors: Aaron S Kesselheim; Eric G Campbell; Sebastian Schneeweiss; Paula Rausch; Brian M Lappin; Esther H Zhou; John D Seeger; John S Brownstein; Steven Woloshin; Lisa M Schwartz; Timothy Toomey; Gerald J Dal Pan; Jerry Avorn Journal: Drug Saf Date: 2015-06 Impact factor: 5.606
Authors: Thomas C Neylan; Anne Richards; Thomas J Metzler; Leslie M Ruoff; Jonathan Varbel; Aoife O'Donovan; Melinda Sivasubramanian; Terri Motraghi; Jennifer Hlavin; Steven L Batki; Sabra S Inslicht; Kristin Samuelson; Stephen R Morairty; Thomas S Kilduff Journal: Sleep Date: 2020-10-13 Impact factor: 5.849
Authors: Judith Sys; Simon Van Cleynenbreugel; Mieke Deschodt; Lorenz Van der Linden; Jos Tournoy Journal: Eur J Clin Pharmacol Date: 2019-12-14 Impact factor: 2.953
Authors: Hyungjin Myra Kim; Lauren B Gerlach; Matheos Yosef; Claire Stano; Deirdre A Conroy; Marcia Valenstein; Paul N Pfeiffer; Anne E Sales; Kara Zivin Journal: J Clin Sleep Med Date: 2018-07-15 Impact factor: 4.062
Authors: John N Booth; Michael Behring; Ryan S Cantor; Lisandro D Colantonio; Sherri Davidson; John P Donnelly; Erica Johnson; Kelsey Jordan; Chelsea Singleton; Fenglong Xie; Gerald McGwin Journal: Sleep Med Date: 2015-12-29 Impact factor: 3.492